Quick Answer
UNITED THERAPEUTICS Corp reported Total Revenue of $3.18 billion for fiscal year 2025.
UNITED THERAPEUTICS Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $3.18B +10.6% |
$2.88B +23.6% |
$2.33B +20.2% |
$1.94B +14.9% |
$1.69B +13.6% |
$1.48B +2.4% |
| Revenue (ASC 606) | $3.18B +10.6% |
$2.88B +23.6% |
$2.33B +20.2% |
$1.94B +14.9% |
$1.69B +13.6% |
$1.48B +2.4% |
| Net Income | $1.33B +11.7% |
$1.20B +21.4% |
$984.80M +35.4% |
$727.30M +52.9% |
$475.80M | — |
| Diluted EPS | $27.86 +13.1% |
$24.64 +24.4% |
$19.81 +32.1% |
$15.00 +49.1% |
$10.06 -12.8% |
$11.54 +582.8% |
| Total Assets | $7.88B +7.0% |
$7.36B +2.7% |
$7.17B +18.6% |
$6.04B +16.9% |
$5.17B +12.0% |
$4.62B +17.9% |
| Cash and Equivalents | $1.56B -8.3% |
$1.70B +40.5% |
$1.21B +25.6% |
$961.20M +7.4% |
$894.80M +21.1% |
$738.70M +0.0% |
| Stockholders Equity | $7.10B +10.1% |
$6.44B +7.7% |
$5.98B +24.8% |
$4.80B +21.2% |
$3.96B +16.6% |
$3.40B +22.1% |
| R&D Expense | $550.00M +14.3% |
$481.00M +17.9% |
$408.00M +26.4% |
$322.90M -40.2% |
$540.10M +51.0% |
$357.70M -69.8% |
| Operating Income | $1.49B +8.4% |
$1.38B +16.2% |
$1.18B +20.9% |
$979.70M +76.2% |
$555.90M -6.4% |
$593.60M +416.4% |
| Shares Outstanding | 43.64M -2.7% |
44.83M -4.7% |
47.04M +2.2% |
46.03M +2.0% |
45.11M +1.3% |
44.51M +1.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $799.50M | +6.8% | +0.1% |
| Revenue (ASC 606) | September 30, 2025 | $799.50M | +6.8% | +0.1% |
| Net Income | September 30, 2025 | $338.70M | +9.6% | +9.4% |
| Diluted EPS | September 30, 2025 | $7.16 | +12.1% | +11.7% |
| Total Assets | September 30, 2025 | $7.35B | +3.2% | -7.0% |
| Cash and Equivalents | September 30, 2025 | $1.34B | -13.8% | -15.9% |
| Stockholders Equity | September 30, 2025 | $6.59B | +8.0% | -8.1% |
| R&D Expense | September 30, 2025 | $127.50M | +23.2% | -4.9% |
| Operating Income | September 30, 2025 | $388.50M | +13.2% | +6.6% |
| Shares Outstanding | September 30, 2025 | 42.90M | -3.8% | -5.1% |
- UNITED THERAPEUTICS Corp reported Total Revenue of $3.18 billion for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +10.6% in Total Revenue compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Revenue (ASC 606) of $3.18 billion for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +10.6% in Revenue (ASC 606) compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Net Income of $1.33 billion for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +11.7% in Net Income compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Diluted EPS of $27.86 per share for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +13.1% in Diluted EPS compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Total Assets of $7.88 billion for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +7.0% in Total Assets compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Cash and Equivalents of $1.56 billion for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed a decrease of -8.3% in Cash and Equivalents compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Stockholders Equity of $7.10 billion for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +10.1% in Stockholders Equity compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported R&D Expense of $550.00 million for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +14.3% in R&D Expense compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Operating Income of $1.49 billion for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed an increase of +8.4% in Operating Income compared to the prior fiscal year.
- UNITED THERAPEUTICS Corp reported Shares Outstanding of 43.64 million shares for fiscal year 2025.
- UNITED THERAPEUTICS Corp showed a decrease of -2.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: